PET/CT shows high value in lung cancer staging trial

October 7, 2008 Diagnostic Imaging. PET/CT shows high value in lung cancer staging trial An in-depth assessment of PET/CT at three German teaching hospitals has shown the fusion imaging technology improves on CT alone and pays dividends clinically and financially for staging non-small cell lung cancer. The research leading to these conclusions was based on evaluations of 205 patients with proven non-small cell lung cancer who were staged with FDG-PET/CT and conventional contrast-enhanced imaging with only the CT component of the hybrid scanner. Follow-up was performed five years after staging to assess survival and clinical status.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC